Vaxil Bio Ltd.
VXLLF
$0.02
-$0.13-85.27%
OTC PK
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 148.10% | 36.21% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 148.10% | 36.21% | |||
| Operating Income | -148.10% | -36.21% | |||
| Income Before Tax | -118.91% | 2,904.83% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -118.91% | 2,904.83% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -118.81% | 2,920.00% | |||
| EBIT | -148.10% | -36.21% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -114.73% | 2,571.70% | |||
| Normalized Basic EPS | -83.33% | -100.00% | |||
| EPS Diluted | -114.73% | 2,571.70% | |||
| Normalized Diluted EPS | -83.33% | -100.00% | |||
| Average Basic Shares Outstanding | 27.64% | 13.94% | |||
| Average Diluted Shares Outstanding | 27.64% | 13.94% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||